Alabama
Birmingham; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Birmingham; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Birmingham; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Montgomery; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Muscle Shoals; Northwest Alabama Cancer Center
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Alaska
Anchorage; Alaska Cancer Research and Education Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Arizona
Phoenix; Precision Trials, LLC![[*]](../images/newtiny.gif)
Breast Scan
Scottsdale; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Scottsdale; Scottsdale Medical Specialists
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Tucson; Arizona Hematology Oncology
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Tucson ; Research Site:
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
Tucson ; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Tucson; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Arkansas
Fayetteville; Highlands Oncology Group
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Fayetteville; Highlands Oncology Group
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Fayetteville; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Hot Springs; Genesis Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Hot Springs; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Jonesboro; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Jonesboro; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Jonesboro; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Little Rock; Research Site:
A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Little Rock; Little Rock Hematology Oncology Associates
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
California
Anaheim; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Bakersfield; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Bakersfield; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Bakersfield; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Bakersfield; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Bakersfield; Comprehensive Blood and Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Baldwin Park; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Bellflower; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Berkeley; Alta Bates Medical Center
Study of the Anti-angiogenesis Agent AG-013736 Plus Docetaxel in Patients with Metastatic Breast Cancer
Beverly Hills; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Beverly Hills; Tower Hematology Oncology Medi
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Burbank; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Campbell; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Campbell; Southbay Onc/Hem Partners
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Chula Vista; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Concord; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Concord; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Concord; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Concord; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Concord; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Duarte; City of Hope
ECOG: E1Y97: Mapping Interactive Cancer Susceptibility Loci
Duarte; City of Hope
Biomarkers, Breast Density, and Risk Reduction Perspectives
Duarte; City of Hope
Phase I-II Trial of ZD1839 (IRESSA), Trastuzumab (Herceptin), and Docetaxel (Taxotere) in Patients with erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma
Duarte; City of Hope
PHII-18: Randomized Phase II Study of Cytoxan, Thiotepa, and Carboplatin (STAMP V) with or without Pamidronate in Patients with High-Risk Primary Breast Cancer
Duarte; City of Hope
SWOG S0500: A Randomized Phase III Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-Up Assessment
Duarte; City of Hope
PHII-87 NCI #7703: Phase I/II Study of a Combination of Suberolyanilde Hydroxyamic Acid (Vorinostat) Plus Paclitaxel and Bevacizumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Breast Cancer
Duarte; City of Hope
Age-Related Changes in Nanoparticle Albumin Bound (nab) Paclitaxel Pharmacokinetics and Pharmacodynamics
Duarte; City of Hope
The Effect of Aromatase Inhibition on the Cognitive Function of Older Patients with Breast Cancer
Duarte; City of Hope
Sister Survivor: African American Breast Cancer Coalition
Duarte; City of Hope
Reducing the Burden of Breast Cancer Among African American and Latina Survivors
Duarte; City of Hope
NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (A1) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
Duarte; City of Hope
SWOG S0221: Phase III Trial of Continuous Schedule AC + G Vs. Every 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
Duarte; City of Hope
NSABP Protocol B-39/RTOG 0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Duarte; City of Hope
NCIC CTG MAP.3 A Phase III Randomized Study of Exemestane vs Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Duarte; City of Hope
Blood Tumor Markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
Duarte; City of Hope
Multicenter Evaluation of Breast Cancer Patients and Outcomes of Care within the National Comprehensive Cancer Network (NCCN)
Duarte; City of Hope
A Phase II, Open Label, Non Compariative, International, Multicenter Study to Assess the Efficacy and Safety of KU-0059436 Given Orally Twice Daily in Patients with Advanced BRCA-1 or BRCA2 Associated Breast Cancer
Duarte; City of Hope
NSABP B-36: A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients With Node-Negative Breast Cancer
Duarte; City of Hope
The Impact of Functional Strain on Psychological and Familial Functioning and Access to Follow-up Care Among Asian American Breast Cancer Survivors
Duarte; City of Hope
CA180004: A Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Advanced Breast Cancer
Duarte; City of Hope
SWOG S0226: Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women with Metastatic Breast Cancer
Duarte; City of Hope
Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Mephalan and Carboplatin, Thiotepa, and Cyclophosphamide (STAMP V)+/-Trastuzumab followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer
Duarte; City of Hope
Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed By Abraxane/Carboplatin (ACAC) +/- Trastuzumab As Neoadjuvant Therapy for Patients with Stage I-III Breast Cancer
Fontana; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Fountain Valley; Pacific Coast Hematology/Oncology Medical Group Inc
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Fountain Valley; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Fountain Valley; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Fountain Valley; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Fountain Valley; Pacific Coast Hematology/Oncology Medical Group, Inc.
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Fountain Valley; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Fresno; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Fresno; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Fullerton; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Fullerton; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Fullerton; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Glendale; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Glendale; Glendale Memorial Hospital & Health Center, Hematology/Oncology Department
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Greenbrae; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Greenbrae; California Cancer Care
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Hayward; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Irvine; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
La Jolla; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
La Jolla; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
La Mesa; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
La Verne; Wilshire Oncology Medical Group, Inc.
A trial of 2 Schedules of Ixabepilone plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Little Rock; California Oncology of the Central Valley
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Long Beach; Breastlink Medical Group Inc
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Long Beach; Breastlink Medical Group Inc
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Long Beach; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Long Beach; Breastlink Medical Group Inc
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Long Beach; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Los Angeles; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Los Angeles; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Los Angeles; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Los Angeles; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Los Angeles; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Los Angeles; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Los Angeles; Research Site:
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Los Angeles; East Valley Hematology And Oncology Medical Group, Inc.
A trial of 2 Schedules of Ixabepilone plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Los Angeles; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Los Angeles; UCLA
A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
Modesto; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Montebello; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Montebello; Clinical Trials & Research Associates, Inc.
Study of the Anti-angiogenesis Agent AG-013736 Plus Docetaxel in Patients with Metastatic Breast Cancer
Montebello; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Monterey Park; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Monterey Park; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Northridge; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Oakland; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Oakland; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Oceanside; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Oxnard; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Palm Springs; Comprehensive Cancer Center
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Palm Springs; Comprehensive Cancer Center
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Palm Springs; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Palm Springs; Palm Springs Desert Regional Medical Center - Comprehensive Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Palm Springs; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Panorama City; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Pomona; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Pomona; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Pomona; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Poway; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Rancho Mirage; Desert Hematology Oncology Medical Group Inc
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Redondo Beach; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Redondo Beach; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Riverside; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Sacramento; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Sacramento; Sutter Cancer Center
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Sacramento; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Sacramento; Sutter Cancer Center
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Sacramento; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
San Diego ; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
San Diego ; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
San Diego ; Research Site:
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
San Diego ; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
San Diego ; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
San Francisco; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
San Francisco; UCSF Comprhensive Cancer Center
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
San Francisco; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
San Francisco; Ucsf-Comprehensive Cancer Center
A trial of 2 Schedules of Ixabepilone plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
San Francisco; Ucsf-Comprehensive Cancer Center
A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
San Francisco; Ucsf-Comprehensive Cancer Center
Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
San Jose; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
San Jose; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Santa Barbara; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Santa Barbara; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Santa Barbara; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Santa Clara; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Santa Clara; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Santa Maria; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Santa Monica; Premiere Oncology
A Study of Dose Dense Adjuvant Chemotherapy Plus Bevacizumab in Breast Cancer
Santa Monica; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Soquel; Cancer Research and Prevention Center
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
South San Francisco ; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
South San Francisco ; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
St Helena; Gregory B. Smith MD
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Stanford; Stanford University School of Medicine
Stress and Breast Cancer Study
Stanford; Stanford University School of Medicine
Study of self-conscious emotions in women living with breast cancer
Valencia; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Vallejo; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Vallejo; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Vallejo; Research Site:
A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Various Cities; Research Center
HER2-positive Metastatic Breast Cancer Study CLBH589C2204
Walnut Creek; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Walnut Creek; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Woodland Hills; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Colorado
Aurora; University of Colorado Hospital - Anschutz Cancer Pavilion
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Aurora; University of Colorado Cancer Center
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Aurora; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Aurora; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Aurora; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Aurora; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Aurora; University Of Colorado Cancer Center
Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
Denver; Rocky Mountain Cancer Centers-Rose
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Fort Collins; Front Range Cancer Specialists
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Longmont; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Wheat Ridge; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Connecticut
Bridgeport; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Fairfield; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Fairfield; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Farmington; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Farmington; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Meriden; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Middlebury; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Middlebury; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Middletown; Connecticut Oncology Group
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Norwich; Eastern Connecticut Hematology & Oncology Associates
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Norwich; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Stamford; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Stamford; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Trumbull; Oncology Associates of Bridgeport
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Trumbull; Oncology Associates of Bridgeport
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Trumbull; Oncology Associates of Bridgeport, P.C.
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Delaware
Newark; Helen Graham Cancer Center Christiana Care Health Services
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Newark; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Florida
Aventura; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Aventura; South Florida Medical Research
Phase II, Clinical Trial For Patients with Prostate Cancer or Breast Cancer with Metastatic Disease
Aventura; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Boca Raton; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Boca Raton; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Boca Raton; Boca Raton Community Hospital Inc
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Boca Raton; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Boca Raton; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Boca Raton; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Bonita Springs; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Bonita Springs; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Boynton Beach; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Boynton Beach; Palm Beach Institute of Hematology and Oncology
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Bradenton; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Brooksville; Pasco Hernando Oncology Associates, Inc
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Brooksville; Pasco Hernando Oncology Associates PA
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Cape Coral; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Cape Coral; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Coral Spring; Northwest Oncology & Hematology Associates
A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
Coral Springs; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Coral Springs; Northwest Hematology/Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Coral Springs; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Davie; Florida Cancer Research Institute
A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
Davie; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Daytona Beach; Halifax Medical Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Fort Lauderdale; Holy Cross Hospital, Michael & Dianne Bienes Cancer Center
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Fort Myers; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Fort Myers; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Fort Myers; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Fort Myers; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Ft Lauderdale; Holy Cross Cancer Center
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Ft Lauderdale; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Ft. Lauderdale; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Gainesville; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Gainesville; Gainesville Hematology Oncology Associates
A Phase II study of Abraxane and Nexavar in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Gainesville; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Gainesville; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Gainesville; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Gainsville; Robert R. Carroll MD PA - Pr
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Hollywood; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Hudson; Florida Cancer Institute
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Jacksonville; Mayo Clinic Jacksonville
Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
Jacksonville; Mayo Clinic Jacksonville
A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
Lake Worth; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Lake Worth; Medical Specialists of the Palm Beaches, Inc.
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Lake Worth; Hematology Oncology Associates
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Lakeland; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Lakeland; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Lakeland; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Lakeland; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Melbourne; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Melbourne; Melbourne Internal Medicine Associates
Study of the Anti-angiogenesis Agent AG-013736 Plus Docetaxel in Patients with Metastatic Breast Cancer
Miami; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Miami; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Miami; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Miami; Research Site:
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Miami; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Naples; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Naples; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
New Port Richey; Pasco Hernando Oncology Associates PA
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
New Port Richey; Pasco Hernando Oncology Associates PA
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Orange Park; Florida Oncology Associates/Division of Clinical Research
Study of the Anti-angiogenesis Agent AG-013736 Plus Docetaxel in Patients with Metastatic Breast Cancer
Orlando; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Orlando; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Orlando; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Orlando; Florida Hospital Cancer Institute
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Orlando; Florida Hospital Cancer Institute
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Orlando; M.D. Anderson Cancer Center Orlando
A trial of 2 Schedules of Ixabepilone plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Orlando; M.D. Anderson Cancer Center Orlando
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Orlando; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Plantation; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Plantation; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Plantation; Research Site:
A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Plantation; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Port Charlotte; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Port Charlotte; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Port St Lucie; Research Site:
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
Port St. Lucie; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Port St. Lucie; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Port St. Lucie; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Sarasota ; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Sarasota ; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Sarasota ; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
St. Petersburg; Gulfcoast Oncology Associates
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Tamarac; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Tamarac; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Tampa; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Tampa; Bay Area Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Venice; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
West Palm Beach; Palm Beach Cancer Institute
The purpose of this study is to determine whether RTA 744 is effective in the treatment of breast cancer that has metastasized to the brain.
West Palm Beach; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Georgia
Albany; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Altanta; Peachtree Hematology & Oncology Associates
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Athens; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Atlanta; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Atlanta; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Atlanta; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Atlanta; Emory University
A trial of 2 Schedules of Ixabepilone plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Augusta; Augusta Oncology Associates
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Augusta; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Augusta; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Augusta; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Gainesville; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Lawrenceville; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Macon; Central Georgia Cancer Care
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Macon ; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Marietta; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Marietta; NW Georgia Oncology Center
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Marietta; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Marietta; Northwest Georgia Onc Ctrs PC
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Marietta; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Marietta; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Marietta; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Marietta; Northwest Georgia Oncology Centers, PC
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Savannah; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Savannah; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Savannah; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Savannah; Memorial Health University Medical Center
ACOSOG Z1031: A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Drugs in Postmenopausal Women with Clinical Stage II/III Breast Cancer
Stockbridge; Center of Hope for Cancers and Blood Disorders
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Tucker; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Tucker; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Tucker; Research Site:
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Tucker; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Idaho
Boise; Mtn States Tumor Institute
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Boise; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Coeur D'Alene; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Coeur D'Alene; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Illinois
Arlington Heights; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Chicago; Hematology Oncology Associates of Illinois
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Chicago; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Chicago; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Chicago; Research Site:
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Chicago; University of Chicago, Department of Hematology/Oncology
Study of the Anti-angiogenesis Agent AG-013736 Plus Docetaxel in Patients with Metastatic Breast Cancer
Chicago,; Robert H Lurie Comprehensive Cancer Center at Northwestern University
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Decatur; Cancer Care Specialists of Central Illinois
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Elgin; Sherman Health Systems
SWOG S0226 "Phase III randomized trial of anastrozole versus anastrozole and fluvestrant as first line therapy for post menopausal women with metastatic breast cancer"
Eligible patients will be randomized into one of two study groups: Arm 1 Anastrozole crossover to fulvestrant Arm 2 Anastrozole and fulvestrant
Elgin; Sherman Health Systems
(URCC U1105) Prevention of delayed nausea-- a phase III double-blind placebo-controlled clinical trial for breast cancer patients who are chemotherapy naïve
Elgin; Sherman Health Systems
NSABP B-36 A clinical trial of adjuvant therapy comparing six cycles of 5-FU (5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to four cycles of Adriamycin and Cyclophosphamide (AC) with or without Celecoxib, in patients with node-negative breast cancer.
Elk Grove Village; Alexian Brothers Cancer Institute
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Galesburg; Medical & Surgical Specialists
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Harvey; Ingalls Memorial Hospital / Cancer Research Center
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Harvey; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Joliet; Midwest Center for Hematology Oncology
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Maywood; Loyola University Medical Center
Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
Maywood; Loyola University Medical Center
A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
Napersville; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Naperville; Hem Onc Consultants Ltd
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Park Ridge; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Peoria; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Peoria; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Quincy; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Quincy; Quincy Medical Group
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Skokie; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Skokie; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Skokie; Edward H Kaplan MD & Assoc dba: Hematology/Oncology of the North Shore
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Skokie; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Zion; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Indiana
Beech Grove; Research Site:
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
Bloomington; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Ft. Wayne; Fort Wayne Medical Oncology and Hematology, Inc.
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Indianapolis; American Health Network of Indiana LLC, Oncology Division
Advanced and/or Metastatic Breast Cancer
Indianapolis; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Indianapolis ; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Indianapolis; Hematology Oncology of Indiana
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Indianapolis ; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Indianapolis ; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Indianapolis; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Munster; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
New Albany; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
New Albany; Cancer Care Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
South Bend; Northern Indiana Cancer Research Consortium
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Vincennes; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Vincennes; Family Medicine of Vincennes Clinical Trial Center
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Vincennes; Biomedical Research Alliance of New York
A clinical study involving an experimental drug used in combination with chemotherapy to treat subjects with previously untreated metastatic breast cancer.
Iowa
Bettendorf; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Bettendorf; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Des Moines; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Iowa City; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Iowa City; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Iowa City; University Of Iowa Hospitals And Clinics
A trial of 2 Schedules of Ixabepilone plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Waterloo; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Kansas
Overland Park; Research Site:
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Westwood; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Wichita; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Wichita; Cancer Center of Kansas
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Kentucky
Crestview Hills; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Crestview Hills; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Louisville; Kentuckiana Cancer Institute PLLC
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Louisville; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Louisville; Kentuckiana Cancer Institute PLLC
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Louisville; Kentuckiana Cancer Institute
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Louisiana
Alexandria; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Baton Rouge; Mary Bird Perkins Cancer Center
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Baton Rouge; Mary Bird Perkins Cancer Center
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Baton Rouge; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Lafayette; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Lafayette; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Lafayette; Acadiana Medical Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Lafayette; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Metairie; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Metairie; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Shreveport; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Maine
Scarborough; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Scarborough; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Scarborough; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Scarborough; Research Site:
A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Scarborough; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Scarborough; Maine Center for Cancer Medicine & Blood Disorders
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Scarbrough; Maine Center for Cancer Medicine
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Maryland
Baltimore; Research Center
A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
Baltimore; Weinberg Cancer Institute at Franklin Square Hospital
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Baltimore; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Baltimore; Research Site:
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
Baltimore; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Baltimore; Cancer Center at Greater Baltimore Medical Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Baltimore; Greater Baltimore Medical Center, Cancer Center
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Baltimore; Harbor View Cancer Center
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Bethesda; Center for Cancer and Blood Disorders
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Bethesda; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Bethesda; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Bethesda; Oncology Care Associates
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Cumberland; Western Maryland Health System Braddock Campus
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Frederick; Research Site:
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
Prince Frederick; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Rockville; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Rockville; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Rockville; Research Site:
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Massachusetts
Boston; Boston Medical Center
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Boston; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Boston; Dana-Farber Cancer Inst
A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
Boston; Dana-Farber Cancer Inst
Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
Peabody; North Shore Medical Center, Cancer Center
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Pittsfield; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Pittsfield; Berkshire Hematology Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Springfield; Baystate Medical Center
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Wellesley; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Worcester; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Michigan
Detroit; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Detroit; Research Site:
A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
Free Soil; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Free Soil; West MI Reg Cancer & Blood Ctr
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Grand Rapids; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Grand Rapids; Cancer & Hem Center of West MI
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Kalamazoo; Kalamazoo Hematology and Oncology
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Kalamazoo; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Kalamazoo; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Lansing; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Saint Joseph; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Saint Joseph; Oncology Care Associates PLLC
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Southfield; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Southfield; Research Site:
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Woodhaven; Research Site:
BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Minnesota
Edina; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Edina; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Maplewood; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Minneapolis; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Minneapolis; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Minneapolis; The University of Minnesota Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Saint Louis Park; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
St Louis Park; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
St. Paul; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Woodbury; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Mississippi
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Missouri
Columbia; Ellis Fischel Cancer Center
A trial of 2 Schedules of Ixabepilone plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer
Jeferson City; Columbia Comprehensive Cancer Care Clinic & Research Institute
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Jefferson City; Columbia Comprehensive Cancer Care Clinic & Research Institute
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Jefferson City; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Kansas City; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Kansas City; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Kansas City; Kansas City Cancer Center
Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
Rolla; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
St Louis; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
St Louis; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
St. Charles; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
St. Joseph; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
St. Louis; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
St. Louis; St. John's Mercy Medical Center, David C. Pratt Cancer Center
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Montana
Billings; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Billings; Hematology Oncology Centers of the Northern Rockies
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Great Falls; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Great Falls; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Great Falls; Research Site:
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Great Falls; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Great Falls; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Nebraska
Lincoln; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Lincoln; Nebraska Hematology-Oncology, P.C.
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Lincoln; Southeast Nebraska Cancer Centre
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Lincoln; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Omaha; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Omaha; Hematology/Oncology Consultants PC
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Omaha; Nebraska Methodist Cancer Center
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Omaha; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Omaha; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Omaha; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Omaha; Nebraska Methodist Hospital
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Omaha; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Nevada
Las Vegas; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Las Vegas; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Las Vegas; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Las Vegas; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
Las Vegas; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Las Vegas; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
New Hampshire
Hooksett; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Lebanon; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Lebanon; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
New Jersey
Basking Ridge; Memorial Sloan-Kettering Cancer Center: Basking Ridge, NJ
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Belleville; Essex Oncology Group of N Jersey PA
Paclitaxel with or without Sorafenib in Treating Patients with Locally Recurrent or Metastatic Breast Cancer
Brick; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
East Brunswick; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Englewood; Drs. Forte, Schleider, & Attas, P.A.
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Hackensack; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Hamilton; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Livingston; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Livingston; St. Barnabas Medical Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Livingston; Saint Barnabas Medical Center Cancer Center
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Livingston; Research Site:
A Study of Epothilone D in Patients With Metastatic Breast Cancer
Long Branch; Monmouth Medical Center
A study to compare 3 different treatment schedules of ABI-007 (Abraxane™) in combination with bevacizumab in women with metastatic breast cancer
Montclair; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Morristown; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Mountain Lakes; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Mountain Lakes; Onc & Hematology Specialists
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Neptune; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Neptune; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
New Brunswick; Research Site:
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
Newark; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Paramus; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Paramus; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Red Bank; Research Site:
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
Summit; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Summit; Research Site:
A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
Various Cities; Research Center
Breast Cancer Study CZOL446E2352
Various Cities; Research Center
HER2-positive Metastatic Breast Cancer Study CLBH589C2204
Voorhees; Research Site
Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer.
Voorhees; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
New Mexico
Albuquerque; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Farmington; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Farmington; San Juan Oncology
A clinical study of an investigational drug designed to help slow the progression of HER2-positive metastatic breast cancer
Santa Fe; Research Site
Paclitaxel With Or Without GW572016 As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer.
Santa Fe; Research Site:
XeNA study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Santa Fe; Research Site
Capecitabine (Xeloda) With Or Without GW572016 For Women With Refractory Advanced Or Metastatic Breast Cancer.
New York
Albany; Research Site:
BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
Armonk; Study Site
GW572016, An Oral Drug For Women With Refractory Metastatic Breast Cancer After First-line Or Second-line Herceptin
Bronx; Albert Einstein Cancer Center
A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
Bronx; Our Lady of Mercy Medical Center - Comprehensive Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Bronx; Research Center
Study of SU011248 Versus Chemotherapy for Patients With Previously Treated Triple Receptor Negative Breast Cancer
Bronx; Research Site
A phase 2 clinical trial evaluating the efficacy and safety of trastuzumab administered in combination with SU011248 in patients with metastatic breast cancer.
Bronx; Montefiore Medical Center
A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
Bronx; Montefiore Medical Center
Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
Commack; Memorial Sloan-Kettering Cancer Center: Suffolk
First or Second Line Metastatic Breast Cancer with previous Avastin therapy
Elmhurst; Research Site:
A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
Elmhurst; Biomedical Research Alliance of New York
A clinical study involving an experimental drug used in combination with chemotherapy to treat subjects with previously untreated metastatic breast cancer.
